🕐 --:--
-- --
عاجل
⚡ عاجل: كريستيانو رونالدو يُتوّج كأفضل لاعب كرة قدم في العالم ⚡ أخبار عاجلة تتابعونها لحظة بلحظة على خبر ⚡ تابعوا آخر المستجدات والأحداث من حول العالم
⌘K
AI مباشر | -- مشاهد مباشر
851,600 مقال 404 مصدر نشط 224 قناة مباشرة 4,980 خبر اليوم
آخر تحديث: منذ 6 ثواني

Global Fund expands commitment to improve access to HIV drug

صحة
ARY News EN
2026/04/14 - 21:08 507 مشاهدة
تحليل ذكي | AI Editorial Analysis
جاري تحليل المقال...
InternationalMust ReadGlobal Fund expands commitment to improve access to HIV drugBy Reuters -Apr 15, 2026The U.S. and the Global Fund to Fight AIDS, Tuberculosis and Malaria are ​stepping up efforts to broaden access to Gilead’s HIV prevention ‌drug, with a goal of reaching 3 million people by 2028. Initial deliveries of the drug, lenacapavir, have reached nine African countries, Global Fund said on Tuesday, adding that it ​would extend the provision of the treatment to 12 additional countries, ​including Dominican Republic, Fiji, Indonesia, Morocco, Rwanda and Thailand. In July ⁠last year, Global Fund, which is an international partnership, and Gilead finalized ​their plans to supply lenacapavir to low-income countries, agreeing to provide enough doses ​to reach up to 2 million people over three years. Doctors Without Borders (MSF), an independent international medical organization, said it is concerned that this does not address the fundamental barriers ​keeping this “game-changing” medicine out of reach for many of those who need ​it most. “Any expanded access to lenacapavir is a good thing, but reaching only one million ‌more ⁠people in three years is a tiny fraction of what’s needed to make a real dent in the HIV epidemic.” said Tom Ellman, director of MSF’s Southern Africa Medical Unit. Lenacapavir is a subcutaneous injection given twice a ​year. It helps to ​overcome problems associated ⁠with daily oral pre-exposure prophylaxis pills (PrEP) such as forgotten doses and difficulties in maintaining a steady supply. The Global ​Fund said early program data indicates that uptake is particularly ​strong among ⁠priority populations, including pregnant and breastfeeding women, adolescent girls and young women, and people accessing such drugs for the first time. Gilead has granted voluntary licenses ⁠to several ​manufacturers to produce generic versions of lenacapavir, ​helping to pave the way for expanded and more affordable supply in the future, Global Fund ​said.
المصدر: ARY News EN | Source: ARY News EN

ملاحظة تحريرية | Editorial Note: نُشر هذا المقال في الأصل بواسطة ARY News EN. خبر (Khabr) هي منصة إعلامية أردنية مرخّصة تعمل بالذكاء الاصطناعي. نضيف قيمة تحريرية من خلال: تحليل ذكي للأخبار، ملخصات تلقائية، رواية صوتية بالذكاء الاصطناعي، ترجمة متعددة اللغات، وتدقيق الحقائق. هدفنا جعل الأخبار أكثر وضوحاً وسهولةً للقارئ العربي.

This article was originally published by ARY News EN. Khabr is a licensed Jordanian AI-powered news platform (Registration #82086). We add editorial value through: AI-powered news analysis, automated summaries, AI audio narration, multi-language translation (Arabic, English, French, Turkish), and AI fact-checking. Our mission is to make news more accessible and understandable for Arabic-speaking audiences worldwide.

مشاركة:

المزيد عن صحة | More on Health

هذا الخبر ضمن تغطية خبر لقسم صحة. نقدّم لك تحليلات ذكية وملخصات يومية لأهم الأخبار من مصادر موثوقة متعددة. المصدر: ARY News EN. يوجد 6 مقالات مرتبطة بهذا الموضوع.

This article is part of Khabr's coverage of Health. We provide AI-powered analysis, summaries, and multi-source aggregation to keep you informed. Source: ARY News EN. Tags: Global Fund, HIV, access to medication.

مقالات ذات صلة

AI
يا هلا! اسألني أي شي 🎤
FREE Free 1GB Internet + Free International Calls

$1 trial — eSIM in 190+ countries — No roaming charges

Download Free
🔍